State Street's new 5.1% passive stake adds to institutional ownership concentration alongside Fidelity and Vanguard. Monitor future 13G amendments for position changes and any potential conversion to 13D if intent shifts.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $56.18entry
- T+1 · 6d ago +4.18%α +2.86% · $58.53
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp disclosed a 5.1% passive stake in Cytokinetics via Schedule 13G, holding 7,143,229 shares as of September 30, 2026. This is a new 5%+ disclosure by State Street, adding to the existing passive positions held by Fidelity and Vanguard. The filing confirms passive intent with no control-related purpose.
Key Financial Metrics
Key Facts
- State Street Corp filed a Schedule 13G disclosing beneficial ownership of 7,143,229 shares of Cytokinetics common stock
- The stake represents 5.1% of shares outstanding as of September 30, 2026
- State Street certifies the shares were acquired and held in the ordinary course of business, not for changing or influencing control
- This is a new 5%+ disclosure; prior 13G filings for Cytokinetics were by Fidelity and Vanguard
- State Street is a bank holding company (HC classification) with subsidiaries including SSGA Funds Management and State Street Global Advisors
Financial Impact
7,143,229 shares valued at approximately $364M based on $7.5B market cap and 5.1% stake
Risk Factors
- Passive 13G filing; no activist intent signaled
- Stake is just above the 5% threshold, not a large conviction position
- No stated plans to increase position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000641 |
| Document: 0000093751-26-000641-index.html | 0000093751-26-000641 |
| Document: 0000093751-26-000641.txt | 0000093751-26-000641 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers